Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company developing investigational cancer therapies. Through these filings, investors can review the company’s official disclosures on financial performance, governance, risk factors and progress of its pipeline programs, including the CD47 inhibitor evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004.
Annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe ALX Oncology’s research and development activities, clinical trial portfolio, expenses related to programs such as evorpacept and ALX2004, and other information relevant to its status as a clinical-stage biotechnology company. These reports also discuss risks associated with drug development, regulatory approval and financing.
Current reports on Form 8-K are used by ALX Oncology to disclose material events. For example, the company has filed 8-Ks to furnish quarterly financial results and to announce changes in its board of directors and committee composition. Such filings may incorporate press releases as exhibits and provide timely updates on corporate developments.
Investors interested in insider transactions can review Forms 3, 4 and 5, which report holdings and changes in ownership by directors, officers and certain shareholders. Proxy statements on Schedule 14A offer additional insight into governance matters and executive compensation.
On Stock Titan, ALX Oncology’s SEC filings are updated as they become available from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key sections and clarify technical language, making it easier to understand complex topics such as clinical trial disclosures, R&D spending and risk factor discussions related to the company’s oncology pipeline.